These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 11365714)

  • 41. Pharmacokinetics, safety and anti-human immunodeficiency virus (HIV) activity of hydroxyurea in combination with didanosine.
    Luzzati R; Di Perri G; Fendt D; Ramarli D; Broccali G; Concia E
    J Antimicrob Chemother; 1998 Oct; 42(4):565-6. PubMed ID: 9818769
    [No Abstract]   [Full Text] [Related]  

  • 42. The role of hydroxyurea in enhancing the virologic control achieved through structured treatment interruption in primary HIV infection: final results from a randomized clinical trial (Pulse).
    Bloch MT; Smith DE; Quan D; Kaldor JM; Zaunders JJ; Petoumenos K; Irvine K; Law M; Grey P; Finlayson RJ; McFarlane R; Kelleher AD; Carr A; Cooper DA
    J Acquir Immune Defic Syndr; 2006 Jun; 42(2):192-202. PubMed ID: 16688094
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Improvement of onychomycosis without antifungal therapy after initiation of highly active anti-retroviral therapy (HAART) in an HIV-infected patient.
    Tachikawa N; Yasuoka A; Oka S
    Jpn J Infect Dis; 1999 Dec; 52(6):245-6. PubMed ID: 10738363
    [No Abstract]   [Full Text] [Related]  

  • 44. Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistance.
    Lori F; Malykh AG; Foli A; Maserati R; De Antoni A; Minoli L; Padrini D; Degli Antoni A; Barchi E; Jessen H; Wainberg MA; Gallo RC; Lisziewicz J
    AIDS Res Hum Retroviruses; 1997 Nov; 13(16):1403-9. PubMed ID: 9359660
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Systematic review of combination antiretroviral therapy with didanosine plus hydroxyurea: a partial solution to Africa's HIV/AIDS problem?
    Sanne I; Smego RA; Mendelow BV
    Int J Infect Dis; 2001; 5(1):43-8. PubMed ID: 11285159
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hydroxychloroquine+ddI+Hydroxyurea antiretroviral trial, AIDS Research Alliance, Los Angeles.
    AIDS Treat News; 1999 Dec; (No 332):8. PubMed ID: 11367131
    [TBL] [Abstract][Full Text] [Related]  

  • 47. DMP 266 and indinavir combination.
    AIDS Patient Care STDS; 1997 Aug; 11(4):287-8. PubMed ID: 11361845
    [No Abstract]   [Full Text] [Related]  

  • 48. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 49. ACTG 343: three drugs better than two for maintaining HIV suppression.
    Bowersox J
    NIAID AIDS Agenda; 1998 Mar; ():1-2, 10-1. PubMed ID: 11365088
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and safety of stavudine plus didanosine in asymptomatic HIV-infected children with plasma HIV RNA below 50,000 copies per milliliter.
    de Mendoza C; Ramos JT; Ciria L; Fortuny C; García FJ; de José MI; Asensi F; Soriano V
    HIV Clin Trials; 2002; 3(1):9-16. PubMed ID: 11819180
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Study shows three drugs better than two.
    AIDS Alert; 1997 Apr; 12(4):39. PubMed ID: 11364145
    [TBL] [Abstract][Full Text] [Related]  

  • 52. d4T and ddI shown to be safe and effective.
    AIDS Patient Care STDS; 1997 Aug; 11(4):287. PubMed ID: 11361844
    [No Abstract]   [Full Text] [Related]  

  • 53. Effect of didanosine, stavudine, and hydroxyurea therapy on apoptosis in CD45RA+ and CD45RO+ T lymphocyte subpopulations.
    Nokta M; Rossero R; Nichols J; Rosenbaum M; Pollard RB
    AIDS Res Hum Retroviruses; 1999 Feb; 15(3):255-64. PubMed ID: 10052756
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combined analysis of two-year follow-up from two open-label randomized trials comparing efficacy of three nucleoside reverse transcriptase inhibitor backbones for previously untreated HIV-1 infection: OzCombo 1 and 2.
    Amin J; Moore A; Carr A; French MA; Law M; Emery S; Cooper DA;
    HIV Clin Trials; 2003; 4(4):252-61. PubMed ID: 12916011
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Didanosine: an updated review of its use in HIV infection.
    Perry CM; Noble S
    Drugs; 1999 Dec; 58(6):1099-135. PubMed ID: 10651392
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Some competition for 1592.
    GMHC Treat Issues; 1997; 11(4/5):10-1. PubMed ID: 11364373
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hydroxychloroquine, hydroxycarbamide, and didanosine as economic treatment for HIV-1.
    Paton NI; Aboulhab J; Karim F
    Lancet; 2002 May; 359(9318):1667-8. PubMed ID: 12020529
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cell-associated HIV-1 RNA in blood as indicator of virus load in lymph nodes. The Swiss HIV Cohort Study.
    Yerly S; Rutschmann OT; Opravil M; Marchal F; Hirschel B; Perrin L
    J Infect Dis; 1999 Sep; 180(3):850-3. PubMed ID: 10438378
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mutations in the pol gene of human immunodeficiency virus type 1 in infected patients receiving didanosine and hydroxyurea combination therapy.
    De Antoni A; Foli A; Lisziewicz J; Lori F
    J Infect Dis; 1997 Oct; 176(4):899-903. PubMed ID: 9333147
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hydroxyurea in the treatment of HIV infection: clinical efficacy and safety concerns.
    Lisziewicz J; Foli A; Wainberg M; Lori F
    Drug Saf; 2003; 26(9):605-24. PubMed ID: 12814330
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.